ArticleAlzheimer's & dementia (New York, N. Y.)2020
Antihypertensive medications ameliorate Alzheimer's disease pathology by slowing its propagation.
Article in Alzheimer's & dementia (New York, N. Y.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Hypertension and Alzheimer's disease pathology at autopsy: A systematic review.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022Pooled it
- Peripheral Syndecan-3 and Neurofilament Light Chain as Complementary Blood Biomarkers for Alzheimer's Disease.International journal of molecular sciences · 2026Article
- Angiotensin II-Stimulating Antihypertensive Medications and Dementia-Related Neuropathology.JAMA network open · 2026Article
- Peripheral Leukocyte Syndecan-3 Is Elevated in Alzheimer's Disease: Evidence from a Human Study.International journal of molecular sciences · 2025Article
- The Use of Antihypertensive Medication and In Vivo Alzheimer's Disease Pathology.Annals of neurology · 2025Article
- Hypertension may associate with cerebral small vessel disease and infarcts through the pathway of intracranial atherosclerosis.Neurobiology of aging · 2025Article
- Formulating Treatment to Cure Alzheimer's Dementia: Approach #2.International journal of molecular sciences · 2024Review
- Using artificial intelligence to learn optimal regimen plan for Alzheimer's disease.Journal of the American Medical Informatics Association : JAMIA · 2023Article
- Past antihypertensive medication use is associated with lower levels of small vessel disease and lower Aβ plaque stage in the brains of older individuals.Neuropathology and applied neurobiology · 2023Article
- Inferring Personalized Treatment Effect of Antihypertensives on Alzheimer's Disease Using Deep Learning.Proceedings. IEEE International Conference on Healthcare Informatics · 2023Article
- Association of vascular and degenerative brain pathologies and past medical history from the National Alzheimer's Coordinating Center Database.Journal of neuropathology and experimental neurology · 2023Article
- Angiotensin II Receptor Blockers Reduce Tau/Aß42 Ratio: A Cerebrospinal Fluid Biomarkers' Case-Control Study.Pharmaceutics · 2023Article
- Using Artificial Intelligence to Learn Optimal Regimen Plan for Alzheimer's Disease.medRxiv : the preprint server for health sciences · 2023Article
- Strategies to reduce sample sizes in Alzheimer's disease primary and secondary prevention trials using longitudinal amyloid PET imaging.Alzheimer's research & therapy · 2021Article
- Promoting Successful Cognitive Aging: A Ten-Year Update.Journal of Alzheimer's disease : JAD · 2021Review
- Antihypertensive medications ameliorate Alzheimer's disease pathology by slowing its propagation.Alzheimer's & dementia (New York, N. Y.) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
introductionMounting evidence supports an association between antihypertensive medication use and reduced risk of Alzheimer's disease (AD). Consensus on possible pathological mechanisms remains elusive.
methodsHuman brain tissue from a cohort followed to autopsy that included 96 cases of AD (46 medicated for hypertension) and 53 pathological controls (33 also medicated) matched for cerebrovascular disease was available from the New South Wales Brain Banks. Quantified frontal cortex amyloid beta (Aβ) and tau proteins plus Alzheimer's neuropathologic change scores were analyzed.
resultsUnivariate analyses found no difference in amounts of AD proteins in the frontal cortex between medication users, but multivariate analyses showed that antihypertensive medication use was associated with a less extensive spread of AD proteins throughout the brain. DISCUSSION: The heterogeneous nature of the antihypertensive medications is consistent with downstream beneficial effects of blood pressure lowering and/or management being associated with the reduced spreading of AD pathology observed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.